Vitiligo - VRFoundation
... All the believes mentioned above are considered by the scientific community to be “per se” unfounded and misleading, even if all of them may bring some true indications for understanding the disease and for finding the cure. Vitiligo is a disease that presently cannot be cured, but still can be trea ...
... All the believes mentioned above are considered by the scientific community to be “per se” unfounded and misleading, even if all of them may bring some true indications for understanding the disease and for finding the cure. Vitiligo is a disease that presently cannot be cured, but still can be trea ...
CME INFORMATION Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations
... strategies have not been well defined. The approval of the first vasopressin receptor antagonist (drugs in this class are also referred to as vaptans, for vasopressin antagonists), conivaptan (Astellas Pharma, U.S., Inc., Northbrook, IL), for clinical use by the US Food and Drug Administration (FDA) i ...
... strategies have not been well defined. The approval of the first vasopressin receptor antagonist (drugs in this class are also referred to as vaptans, for vasopressin antagonists), conivaptan (Astellas Pharma, U.S., Inc., Northbrook, IL), for clinical use by the US Food and Drug Administration (FDA) i ...
benefits and limitations of electroconvulsive therapy
... patients were given this treatment than male patients. The mean age was 60 years with the youngest patient being 18 years and the eldest 92 years. On average patients had to wait for one month before receiving this treatment. There is a steady yearly increase in the number of patients receiving ECT ...
... patients were given this treatment than male patients. The mean age was 60 years with the youngest patient being 18 years and the eldest 92 years. On average patients had to wait for one month before receiving this treatment. There is a steady yearly increase in the number of patients receiving ECT ...
UK guidelines for the use of thyroid function tests
... the American Thyroid Association (ATA) has published guidelines for detection of thyroid dysfunction 4; the ATA and the American Association of Clinical Endocrinologists (AACE) have published guidelines on subclinical thyroid disease 5; and the National Academy of Clinical Biochemistry (NACB) has pu ...
... the American Thyroid Association (ATA) has published guidelines for detection of thyroid dysfunction 4; the ATA and the American Association of Clinical Endocrinologists (AACE) have published guidelines on subclinical thyroid disease 5; and the National Academy of Clinical Biochemistry (NACB) has pu ...
Thyroid Function Tests - British Thyroid Association
... the American Thyroid Association (ATA) has published guidelines for detection of thyroid dysfunction 4; the ATA and the American Association of Clinical Endocrinologists (AACE) have published guidelines on subclinical thyroid disease 5; and the National Academy of Clinical Biochemistry (NACB) has pu ...
... the American Thyroid Association (ATA) has published guidelines for detection of thyroid dysfunction 4; the ATA and the American Association of Clinical Endocrinologists (AACE) have published guidelines on subclinical thyroid disease 5; and the National Academy of Clinical Biochemistry (NACB) has pu ...
BOTOX® Cosmetic Prescribing Information
... Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s). Reduced blinking from BOTOX® Cosmetic injection of the orbicularis muscle can lead to corneal expo ...
... Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s). Reduced blinking from BOTOX® Cosmetic injection of the orbicularis muscle can lead to corneal expo ...
Stacy L. Pineles, M.D. Curriculum Vitae
... 11. Pineles SL, Ela-Dalman N, Rosenbaum AL, Aldave AJ, Velez FG. “Binocular visual function in patients with Boston type I keratoprostheses implantation.” Cornea 2010; 29:1397-400. 12. Pineles SL, Avery RA, Liu GT. “Vitamin B12 Optic Neuropathy in Autism.” Pediatrics 2010; 126:e967-70. 13. Pineles ...
... 11. Pineles SL, Ela-Dalman N, Rosenbaum AL, Aldave AJ, Velez FG. “Binocular visual function in patients with Boston type I keratoprostheses implantation.” Cornea 2010; 29:1397-400. 12. Pineles SL, Avery RA, Liu GT. “Vitamin B12 Optic Neuropathy in Autism.” Pediatrics 2010; 126:e967-70. 13. Pineles ...
Obsessive compulsive disorder
... healthcare professionals • Form the basis for education and training of healthcare professionals • Assist patients and carers in making informed decisions about their treatment and care • Improve communication between healthcare professionals, patients and carers • Help identify priority areas for f ...
... healthcare professionals • Form the basis for education and training of healthcare professionals • Assist patients and carers in making informed decisions about their treatment and care • Improve communication between healthcare professionals, patients and carers • Help identify priority areas for f ...
68th Annual Meeting, Miami Beach, Fla., March 5
... Background: Isotretinoin revolutionized the treatment of acne by improving the cosmetic outcome and decreasing the psychological damage. The use of isotretinoin is associated with significant side effects, such as mucocutaneous involvement, dyslipidemia, and increased liver enzymes. Because liver en ...
... Background: Isotretinoin revolutionized the treatment of acne by improving the cosmetic outcome and decreasing the psychological damage. The use of isotretinoin is associated with significant side effects, such as mucocutaneous involvement, dyslipidemia, and increased liver enzymes. Because liver en ...
Eisenach, John H. MD, et al. “Hyperhidrosis: evolving therapies for a
... axilla, areola of the nipple, and perineum in humans, apocrine gland secretion is of little physiological importance; in other mammals, it may function as a sexual attractant. In nonhyperhidrotic individuals at normal body temperature in a comfortable environment, the low level of sweat production i ...
... axilla, areola of the nipple, and perineum in humans, apocrine gland secretion is of little physiological importance; in other mammals, it may function as a sexual attractant. In nonhyperhidrotic individuals at normal body temperature in a comfortable environment, the low level of sweat production i ...
1428 Assessment Report - Medical Services Advisory Committee
... and cost burdens. Improved management of patients during the acute phase of stroke treatment can save patients’ lives and help to reduce both the clinical and cost burden of stroke. For individuals who have an AIS, the key to effective treatment is early reperfusion of ischaemic brain without causin ...
... and cost burdens. Improved management of patients during the acute phase of stroke treatment can save patients’ lives and help to reduce both the clinical and cost burden of stroke. For individuals who have an AIS, the key to effective treatment is early reperfusion of ischaemic brain without causin ...
IY12A Epirubicin inj pi jan12_1.ai
... 1. Severe local tissue necrosis will occur if there is extravasation during administration. EPIRUBICIN HYDROCHLORIDE must not be given by the intramuscular or subcutaneous route [see Warnings and Precautions (5.9)]. 2. Cardiac toxicity, including fatal congestive heart failure (CHF), may occur eithe ...
... 1. Severe local tissue necrosis will occur if there is extravasation during administration. EPIRUBICIN HYDROCHLORIDE must not be given by the intramuscular or subcutaneous route [see Warnings and Precautions (5.9)]. 2. Cardiac toxicity, including fatal congestive heart failure (CHF), may occur eithe ...
Detectable levels of interleukin-18 in uterine luminal secretions at
... Cytokines are not usually measured in uterine secretions during cycles in which treatment procedures and IVF-ET take place, for fear that direct access to the uterine cavity might adversely affect the chance of pregnancy. Results are thus extrapolated to other cycles, i.e. considered to remain consi ...
... Cytokines are not usually measured in uterine secretions during cycles in which treatment procedures and IVF-ET take place, for fear that direct access to the uterine cavity might adversely affect the chance of pregnancy. Results are thus extrapolated to other cycles, i.e. considered to remain consi ...
Guidelines Extravasation guidelines 2007 Implementation Toolkit
... the vein, you should notice some blood return. If you confirm blood return, the cannula can be glided carefully into position, ready to stop if met with any resistance. Brief blood return may be seen if the needle passes through the lumen of the vein and then out the other wall. However, the return ...
... the vein, you should notice some blood return. If you confirm blood return, the cannula can be glided carefully into position, ready to stop if met with any resistance. Brief blood return may be seen if the needle passes through the lumen of the vein and then out the other wall. However, the return ...
Relvar Ellipta : EPAR - Product Information - EMA
... For patients with moderate to severe hepatic impairment, the 92/22 micrograms dose should be used and patients should be monitored for systemic corticosteroid-related adverse reactions (see section 5.2). Systemic corticosteroid effects Systemic effects may occur with any inhaled corticosteroid, part ...
... For patients with moderate to severe hepatic impairment, the 92/22 micrograms dose should be used and patients should be monitored for systemic corticosteroid-related adverse reactions (see section 5.2). Systemic corticosteroid effects Systemic effects may occur with any inhaled corticosteroid, part ...
Company Presentation
... Opsumit (macitentan) is an orally available endothelin receptor antagonist (ERA) approved for the treatment of PAH in over 45 countries, including the United States in October 2013, the European Union in December 2013 and Japan in March 2015 ...
... Opsumit (macitentan) is an orally available endothelin receptor antagonist (ERA) approved for the treatment of PAH in over 45 countries, including the United States in October 2013, the European Union in December 2013 and Japan in March 2015 ...
Rhinology Maintenance of Certification Review
... own regulations exists, particularly if they are not satisfied with the stringency of the current MOC. There is also a conflict between the desire for change and the transparency of cost effectiveness data on various MOC components. Substantial evidence exists for the need of MOC; studies have shown ...
... own regulations exists, particularly if they are not satisfied with the stringency of the current MOC. There is also a conflict between the desire for change and the transparency of cost effectiveness data on various MOC components. Substantial evidence exists for the need of MOC; studies have shown ...
canadian consensus guidelines for the treatment of seasonal
... status in their own right. Having had the privilege to attend the authors’ first consensus-gathering meeting on the subject, I can bear witness to their thorough review and their tough-minded insistence on valuing sound scientific data, while being appropriately cautious about rubber-stamping clinic ...
... status in their own right. Having had the privilege to attend the authors’ first consensus-gathering meeting on the subject, I can bear witness to their thorough review and their tough-minded insistence on valuing sound scientific data, while being appropriately cautious about rubber-stamping clinic ...
IN THE NAME OF GOD FAKHRADDIN FAIZI
... Treatment of overdose: Monitor serum levels regularly, N-acetylcysteine should be available as a specific antidote; basic life support measures may be necessary. ...
... Treatment of overdose: Monitor serum levels regularly, N-acetylcysteine should be available as a specific antidote; basic life support measures may be necessary. ...
Treatment of hemorrhoids: A coloproctologist`s view
... more likely due to anal fissure and anorectal abscess . A precise history and thorough physical exam ination, including digital rectal examination and anoscopy, are imperative for the diagnosis of hemo rrhoids. Unless bright red blood is clearly seen from hemorrhoids, any patients with rectal blee ...
... more likely due to anal fissure and anorectal abscess . A precise history and thorough physical exam ination, including digital rectal examination and anoscopy, are imperative for the diagnosis of hemo rrhoids. Unless bright red blood is clearly seen from hemorrhoids, any patients with rectal blee ...
Considering and managing allergies in people with asthma
... corticosteroids are more effective in reducing nasal symptoms than other treatments,7, 14 including oral H1-antihistamines14, 16 and montelukast,7, 14 and are at least as effective as intranasal H1-antihistamines.7, 16 The use of intranasal corticosteroids in patients with concomitant allergic rhin ...
... corticosteroids are more effective in reducing nasal symptoms than other treatments,7, 14 including oral H1-antihistamines14, 16 and montelukast,7, 14 and are at least as effective as intranasal H1-antihistamines.7, 16 The use of intranasal corticosteroids in patients with concomitant allergic rhin ...
exenatide - Therapeutic Goods Administration
... Efficacy of exenatide in treatment of type 2 diabetes has been established in 5 pivotal placebo- or active comparator-controlled clinical trials, involving 2,496 patients, 1,498 of whom received exenatide. The primary objectives of these clinical trials were to evaluate glycaemic control, primarily ...
... Efficacy of exenatide in treatment of type 2 diabetes has been established in 5 pivotal placebo- or active comparator-controlled clinical trials, involving 2,496 patients, 1,498 of whom received exenatide. The primary objectives of these clinical trials were to evaluate glycaemic control, primarily ...
ZITHROMAX®
... incubation. Incubation in a 10% CO2 atmosphere will result in lowering of media pH (7.2 to 6.6) within 18 hours and in an apparent reduction of the in vitro potency of azithromycin. Thus, the initial pH of the growth medium should be 7.2-7.4, and the CO2 content of the incubation atmosphere should b ...
... incubation. Incubation in a 10% CO2 atmosphere will result in lowering of media pH (7.2 to 6.6) within 18 hours and in an apparent reduction of the in vitro potency of azithromycin. Thus, the initial pH of the growth medium should be 7.2-7.4, and the CO2 content of the incubation atmosphere should b ...
EWMA Document - European Wound Management Association
... Informed consent maybe expressed or implied. ...
... Informed consent maybe expressed or implied. ...
Ch. 5: Management of COPD 64
... education, reviewed existing COPD guidelines, as well as new information on pathogenic mechanisms of COPD as they developed a consensus document. Many recommendations will require additional study and evaluation as the GOLD program is implemented. A major problem is the incomplete information about ...
... education, reviewed existing COPD guidelines, as well as new information on pathogenic mechanisms of COPD as they developed a consensus document. Many recommendations will require additional study and evaluation as the GOLD program is implemented. A major problem is the incomplete information about ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.